Compugen (NASDAQ:CGEN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Compugen (NASDAQ:CGEN) from a hold rating to a buy rating in a report published on Saturday.

CGEN has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compugen in a report on Wednesday, January 21st. HC Wainwright began coverage on shares of Compugen in a research report on Wednesday, January 7th. They set a “buy” rating and a $4.00 price objective for the company. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $4.00.

Compugen Trading Up 3.4%

NASDAQ:CGEN opened at $2.15 on Friday. Compugen has a fifty-two week low of $1.13 and a fifty-two week high of $2.38. The stock has a fifty day moving average price of $1.85 and a 200-day moving average price of $1.68.

Compugen (NASDAQ:CGEN) last issued its quarterly earnings results on Monday, March 2nd. The biotechnology company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.55. Compugen had a return on equity of 55.68% and a net margin of 48.57%.The company had revenue of $67.33 million for the quarter, compared to analysts’ expectations of $14.30 million. Analysts expect that Compugen will post -0.03 earnings per share for the current year.

Hedge Funds Weigh In On Compugen

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd bought a new stake in Compugen in the fourth quarter valued at approximately $104,000. Bank Hapoalim BM bought a new position in Compugen during the 4th quarter worth approximately $37,000. Security National Bank of Sioux City Iowa IA acquired a new position in shares of Compugen in the 4th quarter worth approximately $38,000. Marshall Wace LLP boosted its stake in shares of Compugen by 135.7% in the 4th quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock valued at $163,000 after purchasing an additional 61,202 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Compugen by 3.9% in the 4th quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock valued at $603,000 after purchasing an additional 14,701 shares during the last quarter. 12.22% of the stock is owned by institutional investors and hedge funds.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.